Novoteris announced that the FDA has granted Orphan Drug Designation for inhaled nitric oxide gas for the treatment of cystic fibrosis. Nitric oxide has shown to be an effective antimicrobial agent against broad spectrum of microbes, including drug resistant strains.
This orphan drug designation was granted based on its pilot trial that demonstrated > 15% increase in lung function following two weeks of therapy with inhaled nitric oxide gas.
Nitric oxide is an endogenous molecule that is important in body signaling and is involved in every organ system, including defense against microorganisms. Exogenous nitric oxide has been demonstrated to be an effective antimicrobial agent against a broad spectrum of microbes, including drug resistant strains. Nitric oxide relaxes vascular smooth muscle and when inhaled produces pulmonary vasodilation.
For more information call (714) 705-4576 or visit Novoteris.com.